TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: changes in body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month variation in global deficit score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enhancement of the aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Enhancement of the pulmonary artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to the Onset of Anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time in the range of 80-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-months survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients Presenting Contrast-induced Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite of preeclampsia, fetal loss and maternal death
Endpoint domain: Mortality/survival
Primary endpoint: Function as measured by the Kujala Anterior Knee Pain Scale (AKPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum Diclofenac Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transvalvular gradient across aortic valve prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upright postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified SCORAD index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Who Achieved ACR 50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total vdH-S Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum scan duration for quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neoadjuvant treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants requiring a hospital admission or emergency department visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: comparison of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: comparison of proteins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comparison of miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of DES-OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of P-SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-Cog v14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AD COMposite Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction in volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic GvHD grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose of immunosuppressive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence and Severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Significant Hematological and Biochemistry Lab Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limited Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Seated Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ease to intubate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retention of competency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rectal temperature >= 38°C
Endpoint domain: Adverse events/effects
Primary endpoint: 7-item Pediatric Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of nevirapine trough (Cmin) plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Morphine-equivalent dose consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain using the visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of time to discharge from the PACU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Measure of time to discharge from hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Who Withdrew Due to Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 24 Hour Creatinine Clearance From Day -1 on Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: inflammatory proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delivery in a facility
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Antenatal care attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Typical weekly drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Alcohol Consumed in Single Occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problematic Drinking
Endpoint domain: Adverse events/effects
Primary endpoint: decrease iron deposition in subcortical deep GM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of enrolled patients by cancer type and treatment regimen overall
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of minority and underserved study participants accrued
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anaerobic threshold (AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary protein pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to alleviation of all primary influenza symptoms and fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of multiple C16G2 Gel administrations
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from Atrial Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Operational feasibility of navigated transcranial magnetic stimulation (nTMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Technical feasibility of nTMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Economic feasibility of nTMS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Identification of the motor cortex by addition of nTMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relationship between BBB disruption and WMH progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the Mean BCI for Male From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Mean PIP1 for Female From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic VOC signature for lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V02max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Memory Function Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional Abilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes of lung function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Twice a Day Oral 150 mg Erlotinib Dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Developing Postoperative Ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to normalization of bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety (type, severity, and frequency of adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with linkable records
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of cardiac high sensitive Troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composition of the gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional failure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Burst pressure of repaired enterotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete ablation of gastric low grade intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of asymptomatic COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperglycaemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean ASES Shoulder Score at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ASES Shoulder Score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the Intracuff Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceived stress scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Jefferson scale of empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in sTfR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall ability to find solutions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Orthostatic cardiovascular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With an Overall Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: without excision surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events Leading to Study Treatment Discontinuation or Dose Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of glutamate availability (mGluR5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/Adverse Event Outcome Measure 1
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of IFN-alpha-2b
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Safety of LACTIN-V
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Prolactin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of women responding to summon
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Imaging changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain of peri-implant soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of tumor positive sentinel lymph node (SLN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Incidence rate of cancer-related VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of recurrent VTE events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence rates of post-VTE bleeding events leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in vasopressors and inotropes use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resolution of clinical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With HDV RNA Decline or TND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of contrast-enhanced ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Penn State Worry Questionnaire - A (PSWQ-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in per cent of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Fatigue Severity Scale (FSS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Self-Reported Craving Reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parkinson Disease Questionnaire (PDQ39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Large and Midsize Follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: dynamic CTC changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Leukemia free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Modified Rankin Scale (mRS) 0-1 (no disability)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number and proportion of subjects experiencing treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Epithelization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants with the Presence of Allograft Interstitial Fibrosis and Tubular Atrophy (IF/TA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression of IF/TA from Month 6 to Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in residual tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H7N9 Vaccine, With and Without Adjuvant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H3N2v Vaccine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Differentially Expressed Genes Based on RNA Expression in Human Immune Cells (A/H7N9 Vaccine, With and Without Adjuvant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood levels of methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Smoking Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Involvement of IGF Axis in Ovarian Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of the TARIS placebo system
Endpoint domain: Adverse events/effects
Primary endpoint: Retention of the TARIS placebo system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Drug Concentration Time Curve From Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Drug-concentration Curve of Midazolam From Zero to Last Time of Quantifiable Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Experiencing Collisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on the 'Monkey Ladder' task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on the 'Spatial Span' task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on the 'Token Search' task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on the 'Spatial Planning' task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on the 'Digit Span' task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on the 'Double Trouble' task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: 6-item Pediatric Anxiety Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum BCVA change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney biopsy pathology results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number, severity and type of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serial Plasmin-antiplasmin complex (PAP complex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross cultural validity of a score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for treatment and improvement in erections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: High risk drug discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-time Curve (AUC [0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Phase Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of correct sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in retinol status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful Common Femoral Artery Cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 10-meter walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscles electromyography (EMG) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre- and post-bronchodilator VEMS value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pepsin level in tracheal aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of auditive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Compliance to exercise training program
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of caregiver-care recipient relationship
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessment of soft tissue pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of residents detecting early neurovasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient satisfaction with regard to timing of CISC teaching
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Dynamic Gait Index (DGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Examination achieved
Endpoint domain: Life impact
Endpoint subdomain: Role functioning